Long-term effects of systemic gene therapy in a canine model of myotubular myopathy

Matthew Elverman; Melissa Goddard; David Mack; Jessica Snyder; Michael Lawlor; Hui Meng; Alan H. Beggs; Ana Buj-Bello; Karine Poulard; Anthony Marsh; Robert Grange; Valerie Kelly; Martin K. Childers

doi:10.1002/mus.25658

Journal articles

Long-term effects of systemic gene therapy in a canine model of myotubular myopathy

Matthew Elverman Melissa Goddard ¹ David Mack Jessica Snyder Michael Lawlor Hui Meng Alan H. Beggs ² Ana Buj-Bello ³ Karine Poulard ¹ Anthony Marsh Robert Grange Valerie Kelly Martin K. Childers ⁴

1 INTEGRARE - Approches génétiques intégrées et nouvelles thérapies pour les maladies rares

2 Genomics Program and Division of Genetics

3 Généthon

4 Wake Forest University

Abstract : X-linked myotubular myopathy (XLMTM), a devastating pediatric disease caused by the absence of the protein myotubularin, results from mutations in the MTM1 gene. While there is no cure for XLMTM, we previously reported effects of MTM1 gene therapy using adeno-associated virus (AAV) vector on muscle weakness and pathology in MTM1-mutant dogs. Here, we followed 2 AAV-infused dogs over 4 years.

Keywords : adeno-associated virus canine gait gene therapy muscle myotubular myopathy neuromuscular disease

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Animal biology

Life Sciences [q-bio] / Genetics

Complete list of metadata

https://hal-univ-evry.archives-ouvertes.fr/hal-02179358
Contributor : Melissa Goddard Connect in order to contact the contributor
Submitted on : Wednesday, July 10, 2019 - 4:40:55 PM
Last modification on : Friday, November 4, 2022 - 3:10:52 AM

Long-term effects of systemic gene therapy in a canine model of myotubular myopathy

Links full text

Identifiers

Collections

Citation

Export

Metrics

39

Long-term effects of systemic gene therapy in a canine model of myotubular myopathy

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

39